Table 3.
Median overall survival (OS) and progression-free survival (PFS) depending on the primary tumor location (left or right colon) and treatment (metastasectomy or not, chemotherapy ± bevacizumab).
| Median survival (95% CI), months | P-value | ||
|---|---|---|---|
| Left colon | Right colon | ||
| OS | |||
| Metastasectomy, all patients | 43.8 (34.5-53.1) | 65.5 (36.7-94.3) | .133 |
| Metastasectomy + bevacizumab | 47.5 (26.1-69.0) | 65.5 (25.2-105.8) | .415 |
| Metastasectomy + no bevacizumab | 37.9 (31.5-44.4) | 56.8 (7.9-105.6) | .294 |
| No metastasectomy + no bevacizumab | 22.2 (18.9-25.4) | 15.5 (14.6-16.5) | .731 |
| Bevacizumab + no metastasectomy | 23.4 (17.7-29.1) | 17.2 (13.6-20.7) | .011 |
| PFS | |||
| Metastasectomy, all patients | 16.3 (11.3-21.2) | 16.5 (2.6-30.4) | .250 |
| Metastasectomy + bevacizumab | 18.0 (14.5-21.5) | 29.7 (15.1-44.3) | .315 |
| Metastasectomy + no bevacizumab | 11.8 (9.7-14.0) | 13.0 (12.6-13.4) | .593 |
| No metastasectomy + no bevacizumab | 8.3 (6.9-9.7) | 5.5 (2.8-8.3) | .078 |
| Bevacizumab + no metastasectomy | 11.5 (9.6-13.5) | 9.8 (7.9-11.7) | .138 |